$21.48
Insights on Lifemd Inc
Revenue is down for the last 2 quarters, 44.85M → 44.14M (in $), with an average decrease of 1.6% per quarter
Netprofit is down for the last 2 quarters, -3.73M → -6.76M (in $), with an average decrease of 81.4% per quarter
In the last 1 year, Healthequity Inc has given 37.1% return, outperforming this stock by 6.0%
1.07%
Downside
Day's Volatility :1.07%
Upside
0.0%
42.5%
Downside
52 Weeks Volatility :46.74%
Upside
7.37%
Period | Lifemd Inc | Index (Russel 2000) |
---|---|---|
3 Months | 3.77% | 0.0% |
6 Months | 13.16% | 0.0% |
1 Year | 31.14% | 0.0% |
3 Years | -11.24% | -22.6% |
Book Value | - $0.02 |
Dividend Share | 0.0 |
Dividend Yield | 10.2% |
Earnings Per Share (EPS) | -2.26 |
Profit Margin | -14.28% |
Operating Margin TTM | -13.98% |
Return On Assets TTM | -23.35% |
Return On Equity TTM | -782.48% |
Revenue TTM | 163.6M |
Revenue Per Share TTM | 4.57 |
Quarterly Revenue Growth YOY | 33.300000000000004% |
Gross Profit TTM | 100.4M |
EBITDA | -16.6M |
Diluted Eps TTM | -2.256 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 8.3M | ↑ 64.68% |
Net Income | -1.2M | ↑ 2.89% |
Net Profit Margin | -14.91% | ↑ 8.95% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 12.5M | ↑ 49.79% |
Net Income | -3.5M | ↑ 184.35% |
Net Profit Margin | -28.3% | ↓ 13.39% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 37.3M | ↑ 199.1% |
Net Income | -60.5M | ↑ 1615.42% |
Net Profit Margin | -162.29% | ↓ 133.99% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 92.9M | ↑ 149.04% |
Net Income | -61.3M | ↑ 1.32% |
Net Profit Margin | -66.03% | ↑ 96.26% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 119.0M | ↑ 28.16% |
Net Income | -45.0M | ↓ 26.59% |
Net Profit Margin | -37.82% | ↑ 28.21% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 152.5M | ↑ 28.15% |
Net Income | -20.6M | ↓ 54.25% |
Net Profit Margin | -13.5% | ↑ 24.32% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 28.1M | ↓ 10.48% |
Net Income | -11.6M | ↑ 37.17% |
Net Profit Margin | -41.16% | ↓ 14.3% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 33.1M | ↑ 17.8% |
Net Income | -10.1M | ↓ 12.89% |
Net Profit Margin | -30.44% | ↑ 10.72% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 35.9M | ↑ 8.51% |
Net Income | -6.7M | ↓ 33.22% |
Net Profit Margin | -18.73% | ↑ 11.71% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 38.6M | ↑ 7.42% |
Net Income | -6.1M | ↓ 9.07% |
Net Profit Margin | -15.86% | ↑ 2.87% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 44.9M | ↑ 16.18% |
Net Income | -3.7M | ↓ 39.04% |
Net Profit Margin | -8.32% | ↑ 7.54% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 44.1M | ↓ 1.6% |
Net Income | -6.8M | ↑ 81.36% |
Net Profit Margin | -15.33% | ↓ 7.01% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 2.6M | ↑ 107.0% |
Total Liabilities | 1.8M | ↑ 180.26% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 3.4M | ↑ 31.73% |
Total Liabilities | 4.6M | ↑ 154.7% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 13.1M | ↑ 278.79% |
Total Liabilities | 13.9M | ↑ 203.26% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 49.9M | ↑ 282.45% |
Total Liabilities | 24.1M | ↑ 73.72% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 25.7M | ↓ 48.59% |
Total Liabilities | 33.0M | ↑ 36.79% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 58.5M | ↑ 127.85% |
Total Liabilities | 52.9M | ↑ 60.49% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 25.7M | ↓ 23.07% |
Total Liabilities | 33.0M | ↑ 8.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 33.9M | ↑ 31.96% |
Total Liabilities | 41.2M | ↑ 25.05% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 35.4M | ↑ 4.65% |
Total Liabilities | 45.7M | ↑ 10.72% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 40.7M | ↑ 14.8% |
Total Liabilities | 51.8M | ↑ 13.41% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 58.5M | ↑ 43.72% |
Total Liabilities | 52.9M | ↑ 2.2% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 61.5M | ↑ 5.09% |
Total Liabilities | 60.2M | ↑ 13.69% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -905.5K | ↑ 10.81% |
Investing Cash Flow | 141.4K | ↑ 0.0% |
Financing Cash Flow | 802.8K | ↑ 3.45% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 251.4K | ↓ 127.76% |
Investing Cash Flow | -100.0K | ↓ 170.7% |
Financing Cash Flow | 775.1K | ↓ 3.45% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.1M | ↓ 4925.47% |
Investing Cash Flow | -798.1K | ↑ 698.14% |
Financing Cash Flow | 21.0M | ↑ 2609.53% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -33.1M | ↑ 172.72% |
Investing Cash Flow | -3.4M | ↑ 326.28% |
Financing Cash Flow | 68.6M | ↑ 226.81% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -22.9M | ↓ 30.68% |
Investing Cash Flow | -13.9M | ↑ 308.72% |
Financing Cash Flow | -528.2K | ↓ 100.77% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.0M | ↓ 29.07% |
Investing Cash Flow | -1.8M | ↓ 20.99% |
Financing Cash Flow | 1.9M | ↓ 315.8% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.6M | ↑ 32.75% |
Investing Cash Flow | -2.3M | ↑ 29.94% |
Financing Cash Flow | 12.0M | ↑ 543.94% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.6M | ↓ 277.68% |
Investing Cash Flow | -2.3M | ↑ 0.0% |
Financing Cash Flow | -2.0M | ↓ 116.35% |
Sell
Neutral
Buy
Lifemd Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Lifemd Inc | -3.16% | 13.16% | 31.14% | -11.24% | -11.24% |
Solventum Corp | -11.81% | -17.44% | -17.44% | -17.44% | -17.44% |
Veeva Systems Inc. | -15.62% | -4.25% | -11.39% | -40.54% | 10.17% |
Ge Healthcare Technologies Inc. | -3.32% | 11.22% | -4.15% | 27.54% | 27.54% |
Healthequity Inc | 2.46% | 17.61% | 38.04% | 0.15% | 23.92% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Lifemd Inc | NA | NA | NA | 0.0 | -7.82 | -0.23 | 0.1 | -0.02 |
Solventum Corp | NA | NA | NA | 6.26 | 0.17 | 0.08 | NA | NA |
Veeva Systems Inc. | 51.25 | 51.25 | 1.35 | 4.76 | 0.13 | 0.05 | NA | 28.8 |
Ge Healthcare Technologies Inc. | 22.68 | 22.68 | 20.11 | 4.27 | 0.22 | 0.06 | 0.0 | 16.23 |
Healthequity Inc | 127.63 | 127.63 | 2.29 | 2.19 | 0.03 | 0.03 | NA | 23.63 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Lifemd Inc | Buy | $348.9M | -11.24% | NA | -14.28% |
Solventum Corp | Hold | $10.8B | -17.44% | NA | 15.73% |
Veeva Systems Inc. | Buy | $28.2B | 10.17% | 51.25 | 22.24% |
Ge Healthcare Technologies Inc. | Buy | $35.6B | 27.54% | 22.68 | 8.05% |
Healthequity Inc | Buy | $7.1B | 23.92% | 127.63 | 5.57% |
lifemd is a comprehensive one-stop telemedicine/telehealth solution with a platform that provides a fully integrated telehealth solution to connect physicians, medical providers, pharmacists, and patients worldwide. the platform is hipaa-compliant and all interactions and communication between physicians, healthcare providers and patients are aes-encrypted. the platform allows physicians, healthcare providers and patients to securely connect and manage common medical conditions. lifemd also custom fabricates mobile diagnostic telehealth equipment such as cases, carts and kiosks. the service is available 24/7/365.
Organization | Lifemd Inc |
Employees | 207 |
CEO | Mr. Justin Schreiber |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$21.48
-1.24%
Keyarch Acquisition Corp
$21.48
-1.24%
Connexa Sports Technologies Inc
$21.48
-1.24%
Us Value Etf
$21.48
-1.24%
First Wave Biopharma Inc
$21.48
-1.24%
Global X Msci Next Emerging
$21.48
-1.24%
Fat Projects Acquisition Corp
$21.48
-1.24%
Capital Link Global Fintech
$21.48
-1.24%
Applied Uv Inc
$21.48
-1.24%